{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:02:11Z","timestamp":1773759731999,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11864-025-01302-y","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:38:52Z","timestamp":1740728332000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management"],"prefix":"10.1007","volume":"26","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"1302_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004\u201314. https:\/\/doi.org\/10.1056\/NEJM199504133321507.","journal-title":"N Engl J Med"},{"key":"1302_CR2","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","volume":"13","author":"JE Cortes","year":"1995","unstructured":"Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643\u201355. https:\/\/doi.org\/10.1200\/JCO.1995.13.10.2643.","journal-title":"J Clin Oncol"},{"key":"1302_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/s0140-6736(94)90754-4","volume":"344","author":"K Gelmon","year":"1994","unstructured":"Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344:1267\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(94)90754-4.","journal-title":"Lancet"},{"key":"1302_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790\u2013803. https:\/\/doi.org\/10.1038\/nrd3253.","journal-title":"Nat Rev Drug Discov"},{"key":"1302_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Leb\u0153uf NR, Roche H, Belum VR, Gladieff L, Deslandres M, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26:427\u201343. https:\/\/doi.org\/10.1684\/ejd.2016.2833.","journal-title":"Eur J Dermatol"},{"key":"1302_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00520-023-07852-x","volume":"31","author":"Y Saito","year":"2023","unstructured":"Saito Y, Takekuma Y, Takeshita T, Oshino T, Sugawara M. Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment. Support Care Cancer. 2023;31:372. https:\/\/doi.org\/10.1007\/s00520-023-07852-x.","journal-title":"Support Care Cancer"},{"key":"1302_CR7","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00520-015-2941-0","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, et al. Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer. 2016;24:1583\u201394. https:\/\/doi.org\/10.1007\/s00520-015-2941-0.","journal-title":"Support Care Cancer"},{"key":"1302_CR8","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1007\/s00520-016-3256-5","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, et al. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016;24:3633\u201350. https:\/\/doi.org\/10.1007\/s00520-016-3256-5.","journal-title":"Support Care Cancer"},{"key":"1302_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3892\/ol.2012.651","volume":"3","author":"A Imai","year":"2012","unstructured":"Imai A, Matsunami K, Takagi H, Ichigo S. Proposed medications for taxane-induced myalgia and arthralgia (Review). Oncol Lett. 2012;3:1181\u20135. https:\/\/doi.org\/10.3892\/ol.2012.651.","journal-title":"Oncol Lett"},{"key":"1302_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1078155215627502","volume":"23","author":"N Chiu","year":"2017","unstructured":"Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M, et al. Taxane-induced arthralgia and myalgia: A literature review. J Oncol Pharm Pract. 2017;23:56\u201367. https:\/\/doi.org\/10.1177\/1078155215627502.","journal-title":"J Oncol Pharm Pract"},{"key":"1302_CR11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29:1472\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.33.0308.","journal-title":"J Clin Oncol"},{"key":"1302_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00520-019-04808-y","volume":"28","author":"Y Saito","year":"2020","unstructured":"Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I, et al. Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer. 2020;28:221\u20137. https:\/\/doi.org\/10.1007\/s00520-019-04808-y.","journal-title":"Support Care Cancer"},{"key":"1302_CR13","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1002\/cncr.27489","volume":"118","author":"BN Reeves","year":"2012","unstructured":"Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118:5171\u20138. https:\/\/doi.org\/10.1002\/cncr.27489.","journal-title":"Cancer"},{"key":"1302_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00520-017-3836-z","volume":"26","author":"N Chiu","year":"2018","unstructured":"Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, et al. A prospective study of docetaxel-associated pain syndrome. Support Care Cancer. 2018;26:203\u201311. https:\/\/doi.org\/10.1007\/s00520-017-3836-z.","journal-title":"Support Care Cancer"},{"key":"1302_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633\u201342. https:\/\/doi.org\/10.1200\/JCO.2005.04.0543.","journal-title":"J Clin Oncol"},{"key":"1302_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/PPO.0b013e31815a999b","volume":"13","author":"CL Loprinzi","year":"2007","unstructured":"Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJB, Mantyh P, et al. The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J. 2007;13:399\u2013403. https:\/\/doi.org\/10.1097\/PPO.0b013e31815a999b.","journal-title":"Cancer J"},{"key":"1302_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2016.07.018","volume":"15","author":"R Fernandes","year":"2017","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MFK, Jacobs C, et al. A systematic review of the incidence and risk factors for taxane acute pain syndrome in patients receiving taxane-based chemotherapy for prostate cancer. Clin Genitourin Cancer. 2017;15:1\u20136. https:\/\/doi.org\/10.1016\/j.clgc.2016.07.018.","journal-title":"Clin Genitourin Cancer"},{"key":"1302_CR18","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00520-018-4161-x","volume":"26","author":"R Fernandes","year":"2018","unstructured":"Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, et al. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer. 2018;26:3073\u201381. https:\/\/doi.org\/10.1007\/s00520-018-4161-x.","journal-title":"Support Care Cancer"},{"key":"1302_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/cncr.11578","volume":"98","author":"D Cella","year":"2003","unstructured":"Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer. 2003;98:822\u201331. https:\/\/doi.org\/10.1002\/cncr.11578.","journal-title":"Cancer"},{"key":"1302_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30A","author":"RK Portenoy","year":"1994","unstructured":"Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326\u201336. https:\/\/doi.org\/10.1016\/0959-8049(94)90182-1.","journal-title":"Eur J Cancer"},{"key":"1302_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X.","journal-title":"Lancet"},{"key":"1302_CR22","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1911206.","journal-title":"N Engl J Med"},{"key":"1302_CR23","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized Phase III trial-FIRSTANA. J Clin Oncol. 2017;35:3189\u201397. https:\/\/doi.org\/10.1200\/JCO.2016.72.1068.","journal-title":"J Clin Oncol"},{"key":"1302_CR24","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"1302_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(14)60845-X.","journal-title":"Lancet"},{"key":"1302_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277\u201387. https:\/\/doi.org\/10.1016\/S2468-1253(16)30219-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1302_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00520-023-08082-x","volume":"31","author":"B Tawfik","year":"2023","unstructured":"Tawfik B, Dayao ZR, Brown-Glaberman UA, Pankratz VS, Lafky JM, Loprinzi CL, et al. A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: alliance A22_Pilot2. Support Care Cancer. 2023;31:637. https:\/\/doi.org\/10.1007\/s00520-023-08082-x.","journal-title":"Support Care Cancer"},{"key":"1302_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00520-008-0508-z","volume":"17","author":"T Yoshida","year":"2009","unstructured":"Yoshida T, Sawa T, Ishiguro T, Horiba A, Minatoguchi S, Fujiwara H. The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer. 2009;17:315\u201320. https:\/\/doi.org\/10.1007\/s00520-008-0508-z.","journal-title":"Support Care Cancer"},{"key":"1302_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/bjc.1998.278","volume":"77","author":"H Kunitoh","year":"1998","unstructured":"Kunitoh H, Saijo N, Furuse K, Noda K, Ogawa M. Neuromuscular toxicities of paclitaxel 210 mg m(\u22122) by 3-hour infusion. Br J Cancer. 1998;77:1686\u20138. https:\/\/doi.org\/10.1038\/bjc.1998.278.","journal-title":"Br J Cancer"},{"key":"1302_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1006\/gyno.2001.6168","volume":"81","author":"K Yamamoto","year":"2001","unstructured":"Yamamoto K, Hoshiai H, Noda K. Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin. Gynecol Oncol. 2001;81:333\u20134. https:\/\/doi.org\/10.1006\/gyno.2001.6168.","journal-title":"Gynecol Oncol"},{"key":"1302_CR31","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s00520-018-4571-9","volume":"27","author":"Y Kanbayashi","year":"2019","unstructured":"Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T, et al. Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer. 2019;27:2673\u20137. https:\/\/doi.org\/10.1007\/s00520-018-4571-9.","journal-title":"Support Care Cancer"},{"key":"1302_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2022.05.019","volume":"171","author":"J Zhang","year":"2022","unstructured":"Zhang J, Gao HF, Yang C, Zhu T, Ji F, Yang M, et al. Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial. Eur J Cancer. 2022;171:150\u201360. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.019.","journal-title":"Eur J Cancer"},{"key":"1302_CR33","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1007\/s00520-021-06142-8","volume":"29","author":"M Clemons","year":"2021","unstructured":"Clemons M, Simos D, Sienkiewicz M, Ng T, Zibdawi L, Basulaiman B, et al. A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. Support Care Cancer. 2021;29:5787\u201395. https:\/\/doi.org\/10.1007\/s00520-021-06142-8.","journal-title":"Support Care Cancer"},{"key":"1302_CR34","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1007\/s00520-021-06342-2","volume":"29","author":"Y Saito","year":"2021","unstructured":"Saito Y, Takekuma Y, Kobayashi M, Sakamoto T, Yamashita H, Sugawara M. Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Support Care Cancer. 2021;29:8059\u201367. https:\/\/doi.org\/10.1007\/s00520-021-06342-2.","journal-title":"Support Care Cancer"},{"key":"1302_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3747\/co.v17i4.562","volume":"17","author":"S Saibil","year":"2010","unstructured":"Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, et al. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol. 2010;17:42\u20137. https:\/\/doi.org\/10.3747\/co.v17i4.562.","journal-title":"Curr Oncol"},{"key":"1302_CR36","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28:4562\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.30.7025.","journal-title":"J Clin Oncol"},{"key":"1302_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00520-019-04845-7","volume":"28","author":"R Asthana","year":"2020","unstructured":"Asthana R, Zhang L, Wan BA, Gallo-Hershberg D, Giotis A, Pasetka M, et al. Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study. Support Care Cancer. 2020;28:589\u201398. https:\/\/doi.org\/10.1007\/s00520-019-04845-7.","journal-title":"Support Care Cancer"},{"key":"1302_CR38","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s10787-020-00702-w","volume":"28","author":"KV Pinheiro","year":"2020","unstructured":"Pinheiro KV, Brusco I, Hausen BDS, Moresco RN, Rigo FK, Oliveira SM, et al. Efficacy of the world health organization analgesic ladder in the paclitaxel-induced pain syndrome in rats. Inflammopharmacology. 2020;28:1677\u201389. https:\/\/doi.org\/10.1007\/s10787-020-00702-w.","journal-title":"Inflammopharmacology"},{"key":"1302_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cyto.2003.10.004","volume":"25","author":"L Pusztai","year":"2004","unstructured":"Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25:94\u2013102. https:\/\/doi.org\/10.1016\/j.cyto.2003.10.004.","journal-title":"Cytokine"},{"key":"1302_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12990-015-0005-6","volume":"11","author":"X Yan","year":"2015","unstructured":"Yan X, Maixner DW, Yadav R, Gao M, Li P, Bartlett MG, et al. Paclitaxel induces acute pain via directly activating toll like receptor 4. Mol Pain. 2015;11:10. https:\/\/doi.org\/10.1186\/s12990-015-0005-6.","journal-title":"Mol Pain"},{"key":"1302_CR41","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/glia.23557","volume":"67","author":"X Yan","year":"2019","unstructured":"Yan X, Li F, Maixner DW, Yadav R, Gao M, Ali MW, et al. Interleukin-1beta released by microglia initiates the enhanced glutamatergic activity in the spinal dorsal horn during paclitaxel-associated acute pain syndrome. Glia. 2019;67:482\u201397. https:\/\/doi.org\/10.1002\/glia.23557.","journal-title":"Glia"},{"key":"1302_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ejp.1660","volume":"25","author":"GC Zanata","year":"2021","unstructured":"Zanata GC, Pinto LG, da Silva NR, Lopes AHP, de Oliveira FFB, Schivo IRS, et al. Blockade of bradykinin receptors or angiotensin II type 2 receptor prevents paclitaxel-associated acute pain syndrome in mice. Eur J Pain. 2021;25:189\u201398. https:\/\/doi.org\/10.1002\/ejp.1660.","journal-title":"Eur J Pain"},{"key":"1302_CR43","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1007\/s12035-016-0275-7","volume":"54","author":"I Brusco","year":"2017","unstructured":"Brusco I, Silva CR, Trevisan G, de Campos Velho Gewehr C, Rigo FK, La Rocca Tamiozzo L, et al. Potentiation of paclitaxel-induced pain syndrome in mice by angiotensin I converting enzyme inhibition and involvement of kinins. Mol Neurobiol. 2017;54:7824\u201337. https:\/\/doi.org\/10.1007\/s12035-016-0275-7.","journal-title":"Mol Neurobiol"},{"key":"1302_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/onc.2012.46","volume":"32","author":"K Kikuchi","year":"2013","unstructured":"Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, Hampton ST, et al. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2013;32:286\u201395. https:\/\/doi.org\/10.1038\/onc.2012.46.","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"1302_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/03008200390152214","volume":"44","author":"BD Boyan","year":"2003","unstructured":"Boyan BD, Dean DD, Sylvia VL, Schwartz Z. Steroid hormone action in musculoskeletal cells involves membrane receptor and nuclear receptor mechanisms. Connect Tissue Res. 2003;44(Suppl 1):130\u20135. https:\/\/doi.org\/10.1080\/03008200390152214.","journal-title":"Connect Tissue Res"},{"key":"1302_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.phrs.2007.04.006","volume":"55","author":"KT Vel\u00e1zquez","year":"2007","unstructured":"Vel\u00e1zquez KT, Mohammad H, Sweitzer SM. Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res. 2007;55:578\u201389. https:\/\/doi.org\/10.1016\/j.phrs.2007.04.006.","journal-title":"Pharmacol Res"},{"key":"1302_CR47","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1074\/jbc.274.7.3927","volume":"274","author":"L Jamieson","year":"1999","unstructured":"Jamieson L, Carpenter L, Biden TJ, Fields AP. Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem. 1999;274:3927\u201330. https:\/\/doi.org\/10.1074\/jbc.274.7.3927.","journal-title":"J Biol Chem"},{"key":"1302_CR48","doi-asserted-by":"publisher","first-page":"24124","DOI":"10.1074\/jbc.M601905200","volume":"281","author":"ER LaVallie","year":"2006","unstructured":"LaVallie ER, Chockalingam PS, Collins-Racie LA, Freeman BA, Keohan CC, Leitges M, et al. Protein kinase Czeta is up-regulated in osteoarthritic cartilage and is required for activation of NF-kappaB by tumor necrosis factor and interleukin-1 in articular chondrocytes. J Biol Chem. 2006;281:24124\u201337. https:\/\/doi.org\/10.1074\/jbc.M601905200.","journal-title":"J Biol Chem"},{"key":"1302_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(09)70296-0","volume":"9","author":"DH Lachance","year":"2010","unstructured":"Lachance DH, Lennon VA, Pittock SJ, Tracy JA, Krecke KN, Amrami KK, et al. An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol. 2010;9:55\u201366. https:\/\/doi.org\/10.1016\/S1474-4422(09)70296-0.","journal-title":"Lancet Neurol"},{"key":"1302_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2006.06.043","volume":"405","author":"JM Jimenez-Andrade","year":"2006","unstructured":"Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, Mantyh PW. Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett. 2006;405:62\u20137. https:\/\/doi.org\/10.1016\/j.neulet.2006.06.043.","journal-title":"Neurosci Lett"},{"key":"1302_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.expneurol.2006.07.022","volume":"203","author":"CM Peters","year":"2007","unstructured":"Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. 2007;203:42\u201354. https:\/\/doi.org\/10.1016\/j.expneurol.2006.07.022.","journal-title":"Exp Neurol"},{"key":"1302_CR52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/biology12050755","volume":"12","author":"W Nemoto","year":"2023","unstructured":"Nemoto W, Yamagata R, Nakagawasai O, Tan-No K. Angiotensin-related peptides and their role in pain regulation. Biology (Basel). 2023;12:755. https:\/\/doi.org\/10.3390\/biology12050755.","journal-title":"Biology (Basel)"},{"key":"1302_CR53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41598-024-51572-z","volume":"14","author":"S Iwane","year":"2024","unstructured":"Iwane S, Nemoto W, Miyamoto T, Hayashi T, Tanaka M, Uchitani K, et al. Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. Sci Rep. 2024;14:1039. https:\/\/doi.org\/10.1038\/s41598-024-51572-z.","journal-title":"Sci Rep"},{"key":"1302_CR54","first-page":"271","volume":"17","author":"JA Garrison","year":"2003","unstructured":"Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park). 2003;17:271\u201388.","journal-title":"Oncology (Williston Park)"},{"key":"1302_CR55","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663\u201371. https:\/\/doi.org\/10.1056\/NEJMoa0707056.","journal-title":"N Engl J Med"},{"key":"1302_CR56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13048-023-01216-z","volume":"16","author":"W Gong","year":"2023","unstructured":"Gong W, Yu R, Cao C, Fang Y, Zhao X, Gao Q. Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis. J Ovarian Res. 2023;16:136. https:\/\/doi.org\/10.1186\/s13048-023-01216-z.","journal-title":"J Ovarian Res"},{"key":"1302_CR57","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P. The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89:112\u201328. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.006.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1302_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/1060028017706373","volume":"51","author":"DC Moore","year":"2017","unstructured":"Moore DC, Pellegrino AE, Pain PIB. Pegfilgrastim-Induced Bone Pain: A review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51:797\u2013803. https:\/\/doi.org\/10.1177\/1060028017706373.","journal-title":"Ann Pharmacother"},{"key":"1302_CR59","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2843","volume":"10","author":"D Metcalf","year":"2010","unstructured":"Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer. 2010;10:425\u201334. https:\/\/doi.org\/10.1038\/nrc2843.","journal-title":"Nat Rev Cancer"},{"key":"1302_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1548-5315(11)70402-8","volume":"7","author":"SA Gregory","year":"2010","unstructured":"Gregory SA, Schwartzberg LS, Mo M, Sierra J, Vogel C. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncol. 2010;7:297\u2013308. https:\/\/doi.org\/10.1016\/S1548-5315(11)70402-8.","journal-title":"Community Oncol"},{"key":"1302_CR61","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00520-015-2834-2","volume":"24","author":"H Xu","year":"2016","unstructured":"Xu H, Gong Q, Vogl FD, Reiner M, Page JH. Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer. 2016;24:723\u201330. https:\/\/doi.org\/10.1007\/s00520-015-2834-2.","journal-title":"Support Care Cancer"},{"key":"1302_CR62","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00520-016-3119-0","volume":"24","author":"J Moukharskaya","year":"2016","unstructured":"Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, et al. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer. 2016;24:3085\u201393. https:\/\/doi.org\/10.1007\/s00520-016-3119-0.","journal-title":"Support Care Cancer"},{"key":"1302_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/s0749-0690(05)70079-3","volume":"17","author":"SJ Gibson","year":"2001","unstructured":"Gibson SJ, Helme RD. Age-related differences in pain perception and report. Clin Geriatr Med. 2001;17:433\u201356. https:\/\/doi.org\/10.1016\/s0749-0690(05)70079-3.","journal-title":"Clin Geriatr Med"},{"key":"1302_CR64","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ejp.1011","volume":"21","author":"H El Tumi","year":"2017","unstructured":"El Tumi H, Johnson MI, Dantas PBF, Maynard MJ, Tashani OA. Age-related changes in pain sensitivity in healthy humans: A systematic review with meta-analysis. Eur J Pain. 2017;21:955\u201364. https:\/\/doi.org\/10.1002\/ejp.1011.","journal-title":"Eur J Pain"},{"key":"1302_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/gyno.1998.5226","volume":"72","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol. 1999;72:100\u20131. https:\/\/doi.org\/10.1006\/gyno.1998.5226.","journal-title":"Gynecol Oncol"},{"key":"1302_CR66","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-015-3573-2","volume":"154","author":"AG Waks","year":"2015","unstructured":"Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015;154:359\u201367. https:\/\/doi.org\/10.1007\/s10549-015-3573-2.","journal-title":"Breast Cancer Res Treat"},{"key":"1302_CR67","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist. 2017;22:592\u2013600. https:\/\/doi.org\/10.1634\/theoncologist.2016-0308.","journal-title":"Oncologist"},{"key":"1302_CR68","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782\u201397. https:\/\/doi.org\/10.1200\/JCO.20.01296.","journal-title":"J Clin Oncol"},{"key":"1302_CR69","doi-asserted-by":"publisher","first-page":"9247","DOI":"10.1038\/s41598-023-36264-4","volume":"13","author":"Y Saito","year":"2023","unstructured":"Saito Y, Kanno R, Takekuma Y, Takeshita T, Oshino T, Sugawara M. High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment. Sci Rep. 2023;13:9247. https:\/\/doi.org\/10.1038\/s41598-023-36264-4.","journal-title":"Sci Rep"},{"key":"1302_CR70","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1007\/s00520-017-3760-2","volume":"25","author":"DR Pachman","year":"2017","unstructured":"Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, et al. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017;25:3407\u201316. https:\/\/doi.org\/10.1007\/s00520-017-3760-2.","journal-title":"Support Care Cancer"},{"key":"1302_CR71","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2004.99.298","volume":"22","author":"VH Nguyen","year":"2004","unstructured":"Nguyen VH, Lawrence HJ. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol. 2004;22:1767\u20139. https:\/\/doi.org\/10.1200\/JCO.2004.99.298.","journal-title":"J Clin Oncol"},{"key":"1302_CR72","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00520-015-2807-5","volume":"24","author":"SS Shinde","year":"2016","unstructured":"Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, et al. Can pregabalin prevent paclitaxel-associated neuropathy?\u2013An ACCRU pilot trial. Support Care Cancer. 2016;24:547\u201353. https:\/\/doi.org\/10.1007\/s00520-015-2807-5.","journal-title":"Support Care Cancer"},{"key":"1302_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1315","volume":"369","author":"S Mathieson","year":"2020","unstructured":"Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ. 2020;369: m1315. https:\/\/doi.org\/10.1136\/bmj.m1315.","journal-title":"BMJ"},{"key":"1302_CR74","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.1998.16.12.3918","volume":"16","author":"D Savarese","year":"1998","unstructured":"Savarese D, Boucher J, Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol. 1998;16:3918\u20139. https:\/\/doi.org\/10.1200\/JCO.1998.16.12.3918.","journal-title":"J Clin Oncol"},{"key":"1302_CR75","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s0305-7372(03)00133-6","volume":"29","author":"DMF Savarese","year":"2003","unstructured":"Savarese DMF, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29:501\u201313. https:\/\/doi.org\/10.1016\/s0305-7372(03)00133-6.","journal-title":"Cancer Treat Rev"},{"key":"1302_CR76","first-page":"274","volume":"1","author":"SD Jacobson","year":"2003","unstructured":"Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003;1:274\u20138.","journal-title":"J Support Oncol"},{"issue":"Suppl 7","key":"1302_CR77","first-page":"82","volume":"26","author":"RS DiPaola","year":"1999","unstructured":"DiPaola RS, Schuchter L. Neurologic protection by amifostine. Semin Oncol. 1999;26(Suppl 7):82\u20138.","journal-title":"Semin Oncol"},{"key":"1302_CR78","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.1999.17.10.3038","volume":"17","author":"K Gelmon","year":"1999","unstructured":"Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999;17:3038\u201347. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3038.","journal-title":"J Clin Oncol"},{"key":"1302_CR79","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1023\/a:1011628900089","volume":"12","author":"O Rick","year":"2001","unstructured":"Rick O, Beyer J, Schwella N, Schubart H, Schleicher J, Siegert W. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol. 2001;12:1151\u20135. https:\/\/doi.org\/10.1023\/a:1011628900089.","journal-title":"Ann Oncol"},{"key":"1302_CR80","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00520-016-3467-9","volume":"25","author":"A Jatoi","year":"2017","unstructured":"Jatoi A, Grudem ME, Dockter TJ, Block MS, Villasboas JC, Tan A, et al. A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Support Care Cancer. 2017;25:833\u20138. https:\/\/doi.org\/10.1007\/s00520-016-3467-9.","journal-title":"Support Care Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01302-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T02:04:47Z","timestamp":1742349887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01302-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01302-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies on human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}